197TiP A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859.

Authors :: Qin, S.
Tabernero, J.
van Cutsem, E.
Fuchs, C.S.
Janjigian, Y.Y.
Bhagia, P.
Li, K.
Adelberg, D.
Bang, Y-J.
Source :: Annals of Oncology. 2020 Supplement 6, Vol. 31, pS1316-S1317. 2p.
Publication Year :: 2020

Subjects :: *PEMBROLIZUMAB
*CANCER chemotherapy
*ESOPHAGOGASTRIC junction cancer

Full Text Access

Tools